ClinicalTrials.gg
Enrolling by invitationNCT04708535Updated May 13, 2026

Adaptive Immune Response in Visceral and Subcutaneous Fat: Role in Human Insulin Resistance

An observational study in Insulin Resistance, Insulin Sensitivity and Obesity, sponsored by Stanford University. Enrolling by invitation at 1 site in United States. Open to participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Stanford University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Insulin Resistance by Stanford University — 4 open to participants now, 4 under way, none of them phase 3. Insulin Resistance · Stanford University.

Started
2017
with 1 other
Observational
7 of 33
1 open now
Registered
27th of 33
by date

Among the 33 studies in Insulin Resistance by Stanford University, this one is one of 2 that started in 2017, is one of 7 observational ones, and was the 27th registered.

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

4 of the 33 studies in Insulin Resistance by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Insulin Resistance by Stanford University, or all of them as a file.
02

Study summary

The proposed study is designed to test the hypothesis that in human obesity, the balance of pro- and anti-inflammatory T cells in fat tissue is in fact related to macrophage phenotype and insulin resistance, and how it is related.

This study is needed to confirm whether conclusions based on studies of visceral adipose tissue in mice are indeed applicable to humans.

We also want to determine the relationship between insulin resistance/hyperinsulinemia and ability to lose weight in obese individuals.

Read the detailed description

Previous studies have found convincing evidence of the relationship between insulin resistance, T cell profiles, macrophage profiles and inflammation of the fat cells. This study will add human subjects to that body of evidence.

Overview Aim 1: Test the hypothesis that the balance of anti- inflammatory vs proinflammatory T cells is protective for systemic insulin resistance. T cell profiles in subcutaneous and visceral tissue and blood will be compared in IR vs IS obese humans at baseline and potentially after 12 months following weight loss. Tcell profile will be evaluated for relationships with IR and inflammation, with adjustment for total body fat. Secondarily, they will be evaluated for relationship to adipose cell size.

Overview Aim 2: Test the hypothesis that macrophage phenotype in adipose tissue is associated with T cell profile and IR. Frequency of macrophage phenotypes (M1 vs M2) will be analyzed in IR vs IS obese humans at baseline and potentially after 12 months following weight loss.

Overview Aim 3: Testing the hypothesis insulin resistance is associated with T cell receptor phenotypes in subcutaneous and visceral tissue. IR and IS subjects will be evaluated at baseline by sequencing of expressed TCRs in paired SAT, VAT, and blood. We will determine whether TCR phenotypes are shared between different IR individuals.

03

Conditions studied

  • Insulin Resistance
  • Insulin Sensitivity
  • Obesity
  • Inflammation
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

There are no restrictions in regards to gender, race, or socioeconomic status. The racial/ ethnic composition of the study population will be reflective of the communities surrounding the Stanford University Medical Center.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current patients of Stanford Healthcare, Bariatric Surgery Clinic, scheduled to undergo bariatric surgery (sleeve or RYGB)
  • 30-55kg/m2
  • 30-65 years of age
  • good general health, no major organ disease
  • non-diabetic by current American Diabetes Association (ADA) criteria (fasting glucose \<126mg/dl)

Exclusion criteria

Exclusion Criteria:

  • Subjects with any clinical or biochemical evidence of significant anemia, gastrointestinal, cardiac, hepatic or renal disease will be excluded.
  • Subjects with other medical problems may participate as long as the problems are stable.
  • Subjects with active psychiatric disorders or past history of bariatric surgery
  • Pregnant or lactating women will also be excluded from the study, due to possible risk to the fetus or infant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Bariatric Cohort

    For consenting subjects who are undergoing bariatric surgery, a visceral fat sample will be taken during surgery. In addition to the fat sample, insulin resistance will be measured and determined by a modification of the insulin suppression test.

06

What researchers measure

Primary outcomes

  1. T-cell profile in visceral and subcutaneous fat

    Pro-inflammatory and anti-inflammatory T cell profiles in subcutaneous adipose tissue and visceral adipose tissue measured via flow cytometry.

    Time frame: baseline (within 2 months prior to bariatric surgery)

  2. T-cell profile in visceral and subcutaneous fat

    Pro-inflammatory and anti-inflammatory T cell profiles in subcutaneous adipose tissue and visceral adipose tissue measured via flow cytometry.

    Time frame: post-operatively (1-2 years status post bariatric surgery)

  3. Adipose cell size associated with T cell profile and IR.

    Cell size of subcutaneous adipose tissue and visceral adipose tissue measured via flow cytometry.

    Time frame: baseline (within 2 months prior to bariatric surgery)

  4. Adipose cell size associated with T cell profile and IR.

    Cell size of subcutaneous adipose tissue and visceral adipose tissue measured via flow cytometry.

    Time frame: post-operatively (1-2 years status post bariatric surgery)

  5. Macrophage phenotype

    Frequency of macrophage phenotype (M1 vs M2) in subcutaneous adipose tissue and visceral adipose tissue measured via flow cytometry.

    Time frame: (Timeframe: baseline (within 2 months prior to bariatric surgery)

  6. Macrophage phenotype

    Frequency of macrophage phenotype (M1 vs M2) in subcutaneous adipose tissue and visceral adipose tissue measured via flow cytometry.

    Time frame: post-operatively (1-2 years status post bariatric surgery)

  7. T cell receptor phenotypes

    Frequency of T-cell receptors in subcutaneous adipose tissue and visceral adipose tissue measured via flow cytometry.

    Time frame: (Timeframe: baseline (within 2 months prior to bariatric surgery)

  8. T cell receptor phenotypes

    Frequency of T-cell receptors in subcutaneous adipose tissue and visceral adipose tissue measured via flow cytometry.

    Time frame: post-operatively (1-2 years status post bariatric surgery)

Secondary outcomes

  1. Change in body weight

    Percent body weight loss post bariatric surgery, accounting for insulin sensitivity, T-cell profile, cell size, and macrophage and T-cell phenotypes.

    Time frame: (Timeframe: baseline (within 2 months prior to bariatric surgery)

  2. Change in body weight

    Percent body weight loss post bariatric surgery, accounting for insulin sensitivity, T-cell profile, cell size, and macrophage and T-cell phenotypes.

    Time frame: post-operatively (1-2 years status post bariatric surgery)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2017 (actual). Primary completion is estimated for Aug 2026, 108 months after the start.

Of 130 non-industry observational studies under Insulin Resistance, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 142. This study's planned 108 months is above that.

Counting every sponsor, half of 133 studies reached it within 53 months; a quarter within 18 and three quarters within 142.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2018
First posted
Jan 14, 2021
StartActual
Aug 1, 2017
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04708535
Collaborators
American Heart Association
Responsible party
Tracey McLaughlin (Principal Investigator, Stanford University) — Principal investigator
First posted
Jan 14, 2021
Start date
Aug 1, 2017
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
May 13, 2026

Study contacts

Tracey McLaughlin, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion